Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Medium Chain Triglycerides (MCTs) have some emerging scientific basis for their use in migraine management, though evidence is limited and preliminary. The rationale stems from the observation that migraines may be linked, in part, to impaired energy metabolism in the brain. MCTs are rapidly metabolized into ketone bodies, which can serve as an alternative energy source for the brain, potentially bypassing some metabolic bottlenecks implicated in migraine pathophysiology. Small pilot studies and case reports (such as those evaluating ketogenic diets or exogenous ketone supplementation) have demonstrated a reduction in migraine frequency and severity, with MCT oil sometimes used to help induce mild ketosis or as an adjunct to a ketogenic diet.

However, direct studies on MCT oil alone for migraine are sparse. Most research focuses on broader ketogenic dietary approaches. A few small studies (e.g., Di Lorenzo et al., 2015, and Barbanti et al., 2017) suggest benefits of ketogenic interventions, but do not isolate MCT oil as a sole factor. Thus, while mechanistic logic and limited clinical data support further investigation, robust, large-scale clinical trials are lacking.

In summary, use of MCTs for migraine is based on plausible metabolic mechanisms and some early clinical evidence, but the strength of evidence is currently modest (rated 2/5). It cannot yet be considered a mainstream or fully validated therapy for migraine management.

More about MCT / Medium Chain Triglycerides
More about Migraine

Other ingredients used for Migraine

Other health conditions supported by MCT / Medium Chain Triglycerides

Products containing MCT / Medium Chain Triglycerides